Financial Markets Research: Indevus Pharmaceuticals' Sanctura XR

Summary

Introduction

The lack of differentiation between overactive bladder agents has led manufacturers to turn to large-scale marketing efforts in an attempt to gain market share. Given the relatively small marketing capabilities of IDEV and Esprit, they may have difficulty penetrating high-prescribing urology and primary care practices compared to its larger rivals, thus slowing Sanctura XR's near-term potential.

Highlights

Based on the data from the Phase II trial, we anticipate that once-daily Sanctura XR will demonstrate a safety and efficacy profile comparable to the original twice-daily Sanctura formulation and support its FDA approval in mid/late 2007.Interviewed physicians indicated that all currently marketed OAB products have comparable safety and efficacy profiles and, as the last once-daily OAB option to come to market, if approved, Sanctura XR would not dramatically impact their OAB prescribing habits given the crowded OAB market.

Scope

• Analyzes the commercial potential for IDEV's Sanctura XR, a recently-approved next-generation OAB agent
• Datamonitor interviewed twenty-four urologists regarding trends in the treatment of OAB and the potential role of next-generation Sanctura XRh3>

Reasons to Purchase

• Understand the commercial potential for Sanctura XR in the treatment of OAB through in-depth analysis based on interviews with leading experts
• Anticipate likely changes in the future market dynamics for overactive bladder agents given the entry of a new market player

Content